Juvenescence competitors

Distributed 'PipeCo' building a portfolio of therapeutics that target the biological drivers of aging to extend healthspan.

Aging Drug Discovery · Series C $100M

Aging Drug Discovery

Series C

$100M

HQ

Clinical-stage Swiss biotech developing small-molecule mitophagy inducers to treat age-related and chronic diseases.

Aging Drug Discovery · Series A $32M

Aging Drug Discovery

Series A

$32M

HQ

Combination gene therapies targeting the biology of aging and age-related disease in companion animals and humans.

Aging Drug Discovery · Series A $10M

Aging Drug Discovery

Series A

$10M

HQ

NASDAQ-listed clinical-stage biotech mining human aging data to discover metabolic and inflammatory-aging drugs.

Aging Drug Discovery · IPO $198M

Aging Drug Discovery

IPO

$198M

HQ

Alphabet's aging-research company applying deep biology and drug discovery to age-related disease.

Aging Drug Discovery

Aging Drug Discovery

—

—

HQ

Swiss aging-biotech (formerly Rejuveron) building a portfolio of therapeutics targeting the hallmarks of aging.

Aging Drug Discovery · Series B $75M

Aging Drug Discovery

Series B

$75M

HQ

Singapore biotech applying physics and AI to model human aging and nominate drug targets for age-related disease.

Aging Drug Discovery · Series A extension $6M

Aging Drug Discovery

Series A extension

$6M

HQ